These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1846 related items for PubMed ID: 27566038

  • 21. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Tan GHC, Chia CS, Tan SH, Soo KC, Teo MCC.
    Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
    [Abstract] [Full Text] [Related]

  • 22. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination from Small Bowel Malignancy: Results from a Single Specialized Center.
    Liu Y, Ishibashi H, Takeshita K, Mizumoto A, Hirano M, Sako S, Takegawa S, Takao N, Ichinose M, Yonemura Y.
    Ann Surg Oncol; 2016 May; 23(5):1625-31. PubMed ID: 26717938
    [Abstract] [Full Text] [Related]

  • 23. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y, Li XB, Lin YL, Ma R, Ji ZH, Zhang YB, An SL, Liu G, Yang XJ, Li Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar 25; 24(3):230-239. PubMed ID: 34645167
    [Abstract] [Full Text] [Related]

  • 24. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P.
    Ann Surg Oncol; 2014 Sep 25; 21(9):3023-8. PubMed ID: 24756812
    [Abstract] [Full Text] [Related]

  • 25. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
    Saxena A, Valle SJ, Liauw W, Morris DL.
    Anticancer Res; 2017 Oct 25; 37(10):5737-5742. PubMed ID: 28982894
    [Abstract] [Full Text] [Related]

  • 26. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study.
    Cascales-Campos PA, López-López V, Muñoz-Casares FC, Feliciangeli E, Torres Melero J, Barrios P, Morales R, Ramos I, Ortega G, Camps B, González-Bayón L, Bretcha-Boix P, Farré-Alegre J, González-Moreno S, Gil J.
    Surg Oncol; 2016 Jun 25; 25(2):111-6. PubMed ID: 27312037
    [Abstract] [Full Text] [Related]

  • 27. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
    Canbay E, Mizumoto A, Ichinose M, Ishibashi H, Sako S, Hirano M, Takao N, Yonemura Y.
    Ann Surg Oncol; 2014 Apr 25; 21(4):1147-52. PubMed ID: 24356799
    [Abstract] [Full Text] [Related]

  • 28. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: Risk factors for ICU admission and morbidity prognostic score.
    Malfroy S, Wallet F, Maucort-Boulch D, Chardonnal L, Sens N, Friggeri A, Passot G, Glehen O, Piriou V.
    Surg Oncol; 2016 Mar 25; 25(1):6-15. PubMed ID: 26979635
    [Abstract] [Full Text] [Related]

  • 29. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
    van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer MD, Lemmens VE, de Hingh IH.
    Ann Surg Oncol; 2014 Aug 25; 21(8):2621-6. PubMed ID: 24671638
    [Abstract] [Full Text] [Related]

  • 30. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I, Pereira F, Rihuete Caro C, Pérez-Viejo E, Serrano Á, Gutiérrez Calvo A, Regueira FM, Casado-Adam Á, Cascales-Campos PA, Arteaga X, García-Fadrique A, Gómez Sanz R, López García A, Zozaya G, Arjona Á, Gil Martínez J.
    Ann Surg Oncol; 2019 Aug 25; 26(8):2615-2621. PubMed ID: 31115852
    [Abstract] [Full Text] [Related]

  • 31. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M.
    Ann Surg Oncol; 2014 Mar 25; 21(3):868-74. PubMed ID: 24217789
    [Abstract] [Full Text] [Related]

  • 32. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
    Wagner PL, Austin F, Zenati M, Jaech A, Mavanur A, Ramalingam L, Jones HL, Holtzman MP, Ahrendt SA, Zureikat AH, Pingpank JF, Zeh HJ, Bartlett DL, Choudry HA.
    Ann Surg Oncol; 2016 May 25; 23(5):1587-93. PubMed ID: 26744106
    [Abstract] [Full Text] [Related]

  • 33. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C, Bijelic L, Sugarbaker PH.
    Ann Surg Oncol; 2015 May 25; 22(5):1680-5. PubMed ID: 25120250
    [Abstract] [Full Text] [Related]

  • 34. Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
    Nunez MF, Sardi A, Nieroda C, Jimenez W, Sittig M, MacDonald R, Aydin N, Milovanov V, Gushchin V.
    Ann Surg Oncol; 2015 May 25; 22(5):1658-63. PubMed ID: 25245127
    [Abstract] [Full Text] [Related]

  • 35. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
    Spiliotis J, Argiriou EO, Vafias E, Manou V, Vaos N, Datsis A, Efstathiou E.
    Acta Chir Belg; 2016 Apr 25; 116(2):96-100. PubMed ID: 27385296
    [Abstract] [Full Text] [Related]

  • 36. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    van Eden WJ, Elekonawo FMK, Starremans BJ, Kok NFM, Bremers AJA, de Wilt JHW, Aalbers AGJ.
    Ann Surg Oncol; 2018 Jul 25; 25(7):1992-2001. PubMed ID: 29671139
    [Abstract] [Full Text] [Related]

  • 37. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA, van Oudheusden TR, Luyer MD, Nienhuijs SW, Nieuwenhuijzen GA, Rutten HJ, de Hingh IH.
    Ann Surg Oncol; 2016 Mar 25; 23(3):833-41. PubMed ID: 26442921
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F, Passot G, Villeneuve L, Levine EA, Yonemura Y, Goéré D, Sugarbaker PH, Marolho C, Bartlett DL, Glehen O, BIG-RENAPE Working Group.
    Ann Surg Oncol; 2018 Apr 25; 25(4):1094-1100. PubMed ID: 29238881
    [Abstract] [Full Text] [Related]

  • 40. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
    Lee ZJ, Chia SL, Tan G, Soo KC, Teo CCM.
    Ann Surg Oncol; 2018 Aug 25; 25(8):2340-2346. PubMed ID: 29948417
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 93.